Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback